AgingResearch.NewsJoin free

ANTI-TFR1-MSTN-SIRNA conjugate

Intervention

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab
  • Animals1

Outcomes

3

MSTN

downin mice1−90% greater suppression

1 study

  1. ANTI-TFR1-MSTN-SIRNA conjugate decreases MSTN in mice (90% greater suppression).

    “Terminal analysis revealed 10-18% weight increases in major skeletal muscles, accompanied by 90% greater MSTN mRNA suppression.”

    Animalsco-treated with semaglutide in diet-induced obese miceskeletal muscle

    Antibody-siRNA Conjugate Targeting Myostatin Preserves Muscle Mass during GLP-1R Agonism

    ADA Scientific Sessions 2025 abstract13 Jun 2025

More on MSTN

Lean mass

upin mice1+11% greater lean mass retention

1 study

  1. ANTI-TFR1-MSTN-SIRNA conjugate increases lean mass in mice (11% greater lean mass retention).

    “DIO mice receiving semaglutide plus MSTN conjugate exhibited comparable fat mass reduction but 11% greater lean mass retention versus semaglutide monotherapy.”

    Animalsco-treated with semaglutide in diet-induced obese miceskeletal muscle

    Antibody-siRNA Conjugate Targeting Myostatin Preserves Muscle Mass during GLP-1R Agonism

    ADA Scientific Sessions 2025 abstract13 Jun 2025

Muscle mass

upin mice1+15% δleg area

1 study

  1. ANTI-TFR1-MSTN-SIRNA conjugate increases muscle mass in mice (+14.8% Δleg area).

    “single administration of the conjugate induced dose-dependent muscle mass augmentation lasting >5 weeks, with MSTN-targeting conjugates demonstrating superior efficacy to ActRIIB-targeting counterparts (Δleg area: +14.8% vs +8.6%).”

    Animalssingle administrationskeletal muscle>5 weeks

    Antibody-siRNA Conjugate Targeting Myostatin Preserves Muscle Mass during GLP-1R Agonism

    ADA Scientific Sessions 2025 abstract13 Jun 2025

Latest

Related